Introduction
Precision BioSciences (DTIL) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing product candidates in three high-value areas: allogeneic CAR T immunotherapy, in vivo gene correction and food.
In this article, I will cover an overview of Precision’s technology and clinical pipeline and evaluate their strengths and risk factors, with a primary focus on their allogeneic CAR T immunotherapy platform.
ARCUS genome editing platform
Genome editing is a biotechnology process that removes, inserts or repairs a portion of DNA at a